Hostname: page-component-cd9895bd7-gbm5v Total loading time: 0 Render date: 2024-12-19T12:05:54.305Z Has data issue: false hasContentIssue false

Evidence Into Practice: Prescribing Selective Serotonin Reuptake Inhibitors

Published online by Cambridge University Press:  10 March 2009

Nick Freemantle
Affiliation:
University of York
James M. Mason
Affiliation:
University of York
Ian Watt
Affiliation:
University of York

Abstract

This descriptive analysis examines prescribing trends of antidepressants in English primary care, providing analysis of NHS reimbursement data for groups of antidepressants between 1989 and 1994. Prescribing trends seem unaffected by the release of information on the effectiveness and costeffectiveness of antidepressant drugs. We found that simple distribution of the results of health technology assessments may not be sufficient to influence practice.

Type
Research Note
Copyright
Copyright © Cambridge University Press 1998

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1. Anonymous. Selective serotonin reuptake inhibitors for depression? Drug and Therapeutics Bulletin, 1993, 31, 5758.CrossRefGoogle Scholar
2.Bloor, K., Maynard, A. K., Freemantle, N.Lessons from international experience in controlling pharmaceutical expenditure, III: Regulating industry. British Medical Journal, 1996, 313, 3335.CrossRefGoogle ScholarPubMed
3.Bogle, S. M., Harris, C. M.Measuring prescribing: The shortcomings of the item. British Medical Journal, 1994, 308, 637–40.CrossRefGoogle ScholarPubMed
4.Effective health care: Implementing clinical practice guidelines. Bulletin No 8. Leeds: University of Leeds, 1994.Google Scholar
5.Effective health care: The treatment of depression in primary care. Bulletin No. 5. Leeds: University of Leeds, 1993.Google Scholar
6.Freemantle, N., Grilli, R., Grimshaw, J., et al. Implementing the findings of medical research: The Cochrane Collaboration on Effective Professional Practice. Quality in Health Care, 1995, 4, 4547.CrossRefGoogle ScholarPubMed
7.Freemantle, N., Henry, D., Maynard, A., et al. Promoting cost-effective prescribing: Great Britian lags behind. British Medical Journal, 1995, 310, 955–56.CrossRefGoogle Scholar
8.Freemantle, N., House, A., Song, F., et al. Selective serotonin reuptake inhibitor prescribing as a strategy for the prevention of suicide. British Medical Journal, 1994, 309, 249–53.CrossRefGoogle Scholar
9.Harrison, G.New or old antidepressant? New is better. British Medical Journal, 1994, 309, 1280–81.CrossRefGoogle ScholarPubMed
10.Ibbotson, S. L., Long, A. F., Sheldon, T. A., et al. An initial evaluation of Effective Health Care Bulletins as instruments of effective dissemination. Journal of Management in Medicine, 1993, 7, 4857.CrossRefGoogle Scholar
11.Jönsson, B., & Bebbington, P. E.What price depression? The cost of depression and the cost effectiveness of pharmacological treatment. British Journal of Psychiatry, 1994, 164, 665–73.CrossRefGoogle ScholarPubMed
12.Montgomery, S. A., Henry, J., McDonald, G., et al. Selective serotonin reuptake inhibitors: Meta analysis of discontinuation rates. International Clinical Psychopharmacology, 1994, 9, 4753.CrossRefGoogle ScholarPubMed
13.Owens, D.Benefits of new drugs are exaggerated. British Medical Journal, 1994, 309, 1281–82.CrossRefGoogle ScholarPubMed
14.Song, F., Freemantle, N., Sheldon, T. A., et al. Selection serotonin reuptake inhibitors: Meta-analysis of efficacy and acceptability. British Medical Journal, 1993, 306, 683–87.CrossRefGoogle ScholarPubMed
15.World Health Collaborating Centre for Drug Statistics Methodology. Anatomical Therapeutic Chemical Classification Index. Oslo: World Health Organisation, 1992.Google Scholar